Modality
siRNA
MOA
FGFRi
Target
TROP-2
Pathway
Neuroinflam
UCPNHDravet
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
Jun 2022
→ Mar 2026
Phase 1Current
NCT06882924
2,822 pts·Dravet
2022-06→2026-03·Active
2,822 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-192w agoInterim· Dravet
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P1
Active
Catalysts
Interim
2026-03-19 · 2w ago
Dravet
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06882924 | Phase 1 | Dravet | Active | 2822 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |